Trials / No Longer Available
No Longer AvailableNCT05225259
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Expanded Access of LOXO-260 in Participants With RET Mutant or RET Fusion Tumors Refractory to Prior RET Selective TKI Treatment
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor. The treating physician/investigator contacts Loxo Oncology, Inc. when, based on their medical opinion, a patient meets the criteria for expanded access.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LOXO-260 | Oral |
Timeline
- First posted
- 2022-02-04
- Last updated
- 2024-02-28
Source: ClinicalTrials.gov record NCT05225259. Inclusion in this directory is not an endorsement.